SGL5213

novel intestinal SGLT1 inhibitor

Also Known As:

(1S)-1,5-anhydro-1-(5-((4-((1E)-4-((1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)amino)-3,3-dimethyl-4-oxobut-1-en-1-yl)phenyl)methyl)-2-methoxy-4-(propan-2-yl)phenyl)-D-glucitol

Networked: 5 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Alcohols: 595
  - Sugar Alcohols: 143
    - Sorbitol: 1248
      - SGL5213: 5
Carbohydrates: 22023
- Sugar Alcohols: 143
  - Sorbitol: 1248
    - SGL5213: 5

Experts

1.	Okumura-Kitajima, Lisa: 3 articles (01/2020 - 01/2019)
2.	Yamamoto, Koji: 3 articles (01/2020 - 01/2019)
3.	Kakinuma, Hiroyuki: 2 articles (01/2020 - 01/2019)
4.	Kawabe, Kenichi: 2 articles (01/2020 - 01/2019)
5.	Kimura, Kayo: 2 articles (01/2020 - 06/2019)
6.	Kobashi, Yohei: 2 articles (01/2020 - 01/2019)
7.	Koretsune, Hiroko: 2 articles (01/2020 - 06/2019)
8.	Kuroda, Shoichi: 2 articles (01/2020 - 01/2019)
9.	Shiozawa, Fumiyasu: 2 articles (01/2020 - 01/2019)
10.	Io, Fusayo: 2 articles (06/2019 - 01/2019)

Related Diseases

1.	Non-alcoholic Fatty Liver Disease 10/01/2021 - "In this study, we investigated the protective effect of SGL5213 in a rodent model of NAFLD. " 10/01/2021 - "SGL5213 had a protective effect on the pathogenesis of NAFLD in a rodent model. " 10/01/2021 - "We considered that inhibiting glucose absorption and increasing glucose content in the gastrointestinal tract with SGL5213 might have contributed to the protective effect in NAFLD. " 10/01/2021 - "Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice." 10/01/2021 - "SGL5213 is a promising therapeutic agent for NAFLD with obesity and insulin resistance."
2.	Obesity 10/01/2021 - "SGL5213 is a promising therapeutic agent for NAFLD with obesity and insulin resistance." 10/01/2021 - "SGL5213 and miglitol improved obesity, liver dysfunction, insulin resistance, and the NAFLD severity. "
3.	Liver Diseases (Liver Disease) 10/01/2021 - "SGL5213 and miglitol improved obesity, liver dysfunction, insulin resistance, and the NAFLD severity. "
4.	Insulin Resistance 10/01/2021 - "SGL5213 is a promising therapeutic agent for NAFLD with obesity and insulin resistance." 10/01/2021 - "SGL5213 and miglitol improved obesity, liver dysfunction, insulin resistance, and the NAFLD severity. "
5.	Hyperglycemia 06/15/2019 - "SGL5213 significantly improved post-prandial hyperglycemia in streptozotocin (STZ)-induced diabetic rats at doses of 1 mg/kg or more. "

Related Drugs and Biologics

1.	Streptozocin (Streptozotocin)
2.	Glucosidases
3.	miglitol (Glyset)
4.	Glucose (Dextrose)
5.	Sodium-Glucose Transporter 1
6.	Phenol (Carbolic Acid)
7.	Tyrosine (L-Tyrosine)
8.	Sulfates (Sulfates, Inorganic)
9.	Sorbitol (Yal)
10.	Sodium